Grace Therapeutics, Inc. (GRCE) Research
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Market snapshot
- Symbol
- GRCE
- Price
- $2.38
- Day change
- +7.21%
- Market cap
- $36.8M
- P/E ratio
- -4.14x
- 52-week range
- 1.79-5.18
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 3 days
- Analyst price target
- $4.00
Recent news
- Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
Grace Therapeutics Inc. (NASDAQ:GRCE) shares are down during Friday's premarket session following a regulatory update regarding its New Drug Application (NDA) for GTx-104.
- US FDA declines to approve Grace Therapeutics' drug for a type of stroke
Grace Therapeutics said on Thursday the U.S. Food and Drug Administration declined to approve its drug for a rare type of stroke.
Peer companies
Recent insider activity
- Kavuru Vimal — A-Award (10000 shares) on 2026-01-08
- Kottayil George — A-Award (10000 shares) on 2026-01-08
- NEUGEBOREN EDWARD — A-Award (10000 shares) on 2026-01-08
- DAVIS A BRIAN — A-Award (10000 shares) on 2026-01-08
- Kottayil George — A-Award (10000 shares) on 2025-05-09
Open Grace Therapeutics, Inc. (GRCE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.